drugset / Trial / NCT07290283

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

NCT07290283 ↗

Phase 1 Recruiting 176 enrolled AstraZeneca Parexel · collab
RandomizedSequentialSingle-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent.

Timeline

Start
2025-12-10
Primary completion
2026-10-21
Completion
2026-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD3974 Unknown — Oral

Indications

No indication recorded.